In turn, the antitumor activity of CVF and ketoprofen, but not NGF, is possibly associated with a decrease in the level of serum TGF-β1, which directs the cells of the tumor microenvironment to the pro-tumor phenotype, and negatively regulates the cytotoxic function of immune cells [25,26]. The gene discussed is TGFB1; the disease is neoplasm.